Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Dexmedetomidine on the Liver Injury After Hepatectomy

NCT02833688

Ischemia-reperfusion Injury

COMPLETED PHASE4

High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure

NCT02718079

Acute Liver Failure

COMPLETED NA

High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

NCT03115697

Refractory Hepatic Encephalopathy

WITHDRAWN NA

Study to Evaluate the Efficacy of Intravenous Administration of Human Albumin Versus Saline Solution in Patients With descompénsate Cirrhosis Grade 1B or Higher Renal Failure

NCT07270874

Decompensated Cirrhosis AKI - Acute Kidney Injury

NOT_YET_RECRUITING PHASE4

The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I

NCT04898010

Acute Kidney Injury Hepatorenal Syndrome

SUSPENDED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was \< 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis, Liver AKI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Focus on clinical response after receiving treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dextran 40

Dextran 40 infusion

Group Type EXPERIMENTAL

Dextran 40

Intervention Type DRUG

Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dextran 40

Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Colloidal plasma expander

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Decompensated cirrhosis with acute kidney injury
* Ager over 18 years old

Exclusion Criteria

* Having chronic kidney disease, severe heart or lung disease, severe sepsis
* Pregnant
* Receiving nephrotoxic agents
* Having history of allergic to Dextran

Eligible Sex

ALL

Accepts Healthy Volunteers

No